Neuroendocrine neoplasms (NENs) are heterogenous tumors with incidence and prevalence that continue to increase steadily.
1 Despite their heterogeneity, NENs have historically been grouped homogenously in clinical trials. A prior publication examining the design of therapeutic phase II and III clinical trials in patients with gastroenteropancreatic neuroendocrine tumors (NETs) identified limitations in these studies, such as the inclusion of multiple tumor types, tumors with unspecified differentiation or grade, and nonprogressive tumors.
2 Over the last decade, the adoption of a more advanced pathological classification system has significantly influenced NEN categorization. In particular, the most pronounced addition to the 2019 World Health Organization pathologic classification system for NENs was the definition of the grade 3 well-differentiated NET category, which furthered the distinction between well-differentiated NETs and poorly differentiated neuroendocrine carcinomas (NECs).
3,4 Also over this period of time, from 2010 to 2020, several targeted therapies (ie, everolimus and sunitinib) were licensed by national regulatory bodies and clinical trial design recommendations from the 2011 National Cancer Institute (NCI) NET Clinical Trials Planning Meeting were disseminated.
5-8 Given these advances, in this analysis, we sought to assess whether there had been changes in study design, eligibility, accrual, sponsorship, and outcomes between phase II or III NEN studies that began enrollment between 2000 and 2009 vs between 2010 and 2020.